Thus, it is not known how the various strategies for inhibition of PI3K-Akt-mTOR will influence the balance between antileukemic and potentially AML-supporting activity by immunocompetent BM cells (e.g., monocytes/macrophages, T cells). The gene discussed is AKT1; the disease is acute myeloid leukemia.